Company: BIVIW
Filing Date: 2025-07-11
Form Type: S-1/A
Source: 0001520138-25-000205
Chunk: 115

Company: BIOVIE INC.
Filing Date: 2025-07-11
Form: S-1/A
Chunk 115
---
 as the CEO of Decision Resources Group (DRG), which he transformed into a leading healthcare
data and analytics firm. Prior to that, Jim was CEO of IHS Cambridge Energy Research Associates (IHS CERA), a recognized leader in energy
industry subscription information products, and formerly the President of Strategic Decisions Group (SDG), a leading global strategy consultancy.
Mr. Lang holds a BS summa cum laude in electrical and computer engineering from the University of New Hampshire and an MBA with Distinction
from the Tuck School of Business. Jim Lang currently also serves as a Director at OptimizeRX (OPRX), a Nasdaq listed Company.

Jim Lang’s qualifications to serve on our Board of Directors
are primarily based on his decades of experience as a strategy consultant, broad industry expertise, and senior-level management experience
running several healthcare and information technology companies.

Mr. Sigmund (Sig) Rogich has served as the Company’s director
since June 2020. Sig is the CEO and President of The Rogich Communications Group and serves on the Board of Keep Memory Alive, a philanthropic
organization which raises awareness about brain disorders and Alzheimer’s disease. Keep Memory Alive funds clinical trials to advance
new treatments for patients with Alzheimer’s, Huntington’s and Parkinson’s disease, as well as multiple sclerosis. Mr.
Rogich was formerly the U.S. Ambassador to Iceland. He has served as a senior consultant to Presidents Ronald Reagan and George H.W. Bush.
Mr. Rogich serves on multiple boards of directors for charitable causes.

We believe Mr. Rogich’s qualifications to serve on our Board
of Directors are based on his experience in the Communications sector and philanthropic organization raising awareness about brain disorders.
His experience in service as a senior consultant to candidates of the highest office.

Mr. Michael Sherman, JD has served as the Company director since
2017. He retired from his position as a Managing Director at Barclays Plc in 2018, where he had worked since 2008. Previously he was a
Managing Director at Lehman Brothers, Inc. He has worked in investment banking for 30 years. Mr. Sherman has significant experience in
healthcare finance, most recently assisting on a $450 million convertible transaction for Neurocrine Biosciences. He has worked on successful
financial transactions for Teva Pharmaceutical Industries, Amgen Inc., Cubist Pharmaceuticals, Merck & Co., and Cardinal Health, among
other companies. After graduating from the University of Pennsylvania, Michael Sherman received his